Vericel Corporation

NasdaqGM VCEL

Vericel Corporation Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2024: 71.47%

Vericel Corporation Gross Profit Margin is 71.47% for the Trailing 12 Months (TTM) ending September 30, 2024, a 5.62% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.
  • Vericel Corporation Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was 67.66%, a 2.07% change year over year.
  • Vericel Corporation Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was 66.29%, a -3.48% change year over year.
  • Vericel Corporation Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was 68.68%, a 2.38% change year over year.
  • Vericel Corporation Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2020 was 67.08%, a -0.71% change year over year.
Key data
Date Gross Profit Margin Operating Income Margin EBT Margin Net Income Margin
Market news
Loading...
NasdaqGM: VCEL

Vericel Corporation

CEO Mr. Dominick C. Colangelo Esq.
IPO Date Feb. 4, 1997
Location United States
Headquarters 64 Sidney Street
Employees 314
Sector Health Care
Industries
Description

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

Similar companies

MRUS

Merus N.V.

USD 39.01

-3.56%

DYN

Dyne Therapeutics, Inc.

USD 15.00

-1.90%

SNDX

Syndax Pharmaceuticals, Inc.

USD 12.60

-1.56%

CMRX

Chimerix, Inc.

USD 3.37

1.81%

MREO

Mereo BioPharma Group plc

USD 3.06

-8.38%

RVMD

Revolution Medicines, Inc.

USD 39.83

-6.44%

RLAY

Relay Therapeutics, Inc.

USD 4.35

-9.00%

TERN

Terns Pharmaceuticals, Inc.

USD 4.57

-4.79%

CRNX

Crinetics Pharmaceuticals, Inc.

USD 35.62

-8.62%

PLRX

Pliant Therapeutics, Inc.

USD 11.24

-4.50%

DAWN

Day One Biopharmaceuticals, Inc.

USD 11.16

-3.46%

IPSC

Century Therapeutics, Inc.

USD 0.94

-3.60%

STOK

Stoke Therapeutics, Inc.

USD 8.68

-2.69%

CLGN

CollPlant Biotechnologies Ltd.

USD 3.84

-2.29%

CYTK

Cytokinetics, Incorporated

USD 45.23

-3.17%

XNCR

Xencor, Inc.

USD 19.11

-5.68%

BPMC

Blueprint Medicines Corporation

USD 102.56

-0.77%

IDYA

IDEAYA Biosciences, Inc.

USD 22.74

-1.00%

KROS

Keros Therapeutics, Inc.

USD 12.48

-2.65%

RGNX

REGENXBIO Inc.

USD 7.05

1.44%

StockViz Staff

January 15, 2025

Any question? Send us an email